A Single-Center Study of RO5508887 in Healthy Volunteers

A Single-Center, Randomized, Investigator/Subject-Blind, Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects

This single-center, randomized, double-blind, placebo-controlled study will evaluate the safety, pharmacokinetics and pharmacodynamics of RO5508887 in healthy volunteers. Volunteers will receive multiple-ascending doses of RO5508887 or matching placebo. The anticipated time on study treatment is 14 days.

Inclusion Criteria:

• Adult healthy volunteers, >/=18 years of age
• Body mass index (BMI) between 18 and 30 kg/m2 inclusive
• Use of adequate contraception methods or surgically sterile

Exclusion Criteria:

• Evidence of active or chronic disease
• Regular consumption of drugs of abuse
• Regular smoker (>5 cigarettes per day)
• Infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV)
• History of significant allergic reactions
• Abnormal blood pressure
• Clinical significant abnormalities (e.g., cardiovascular, laboratory values)